Ironwood Pharma (IRWD) Misses Q4 EPS by 3c, provides guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q4 EPS of ($0.01), $0.03 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $47.71 million versus the consensus estimate of $62.43 million.

GUIDANCE:

Ironwood Pharma sees FY2026 revenue of $450-475 million, versus the consensus of $410.5 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Contango Silver & Gold starts drilling at Lucky Shot, updates on key projects
• 3M and Airbus sign long-term insulation deal for A220 aircraft